Wie hoch ist der Preis für Metagenomi, Inc. Common Stock (MGX)

Preis für Metagenomi, Inc. Common Stock (MGX) ist $1.21

Wie hoch ist die Marktkapitalisierung für Metagenomi, Inc. Common Stock (MGX)

Marktkapitalisierung für Metagenomi, Inc. Common Stock (MGX) ist $45.55M

Metagenomi, Inc. Common Stock (MGX) Operative Marge

Metagenomi, Inc. operates as a biotechnology company focused on gene editing, committed to developing therapeutic solutions for patients. The company utilizes a distinctive genome editing toolkit, sourced from metagenomics, for its development efforts within the United States. This advanced toolkit comprises programmable nucleases, base editors, and sophisticated RNA and DNA-mediated integration systems, notably prime editing and CRISPR-associated transposases. Metagenomi has established several key collaborations: a strategic alliance with ModernaTX, Inc. to explore new genome editing systems for in vivo human therapeutic applications; a development and licensing agreement with Affini-T Therapeutics, Inc. to create and commercialize gene-edited T-cell receptor therapies for human cancer; and a partnership with Ionis Pharmaceuticals, Inc. to research, develop, and market investigational medicines leveraging genome editing technologies. Founded in 2016, the company is based in Emeryville, California.

Jahr	Operative Marge	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

Operative Marge

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	Operative Marge	Differenz der operativen Marge	Land
Vertex Pharmaceuticals Incorporated VRTX.US	38.59%	-	US
Argenx SE ARGX.US	28.81%	-	NL
CSL Limited CSL.AX	25.72%	-	AU
Lonza Group AG LONN.SW	0.00%	-	CH
Moderna, Inc. MRNA.US	-149.01%	-	US

Unternehmen

Operative Marge

Differenz der operativen Marge

Land